Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) have earned an average rating of “Moderate Buy” from the seven analysts that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $7.0833.

Several analysts have commented on XERS shares. HC Wainwright started coverage on shares of Xeris Biopharma in a research report on Tuesday, August 12th. They issued a “buy” rating and a $10.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Xeris Biopharma in a research report on Saturday, September 27th. Leerink Partners boosted their target price on shares of Xeris Biopharma from $7.00 to $9.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 19th. Finally, Wall Street Zen downgraded shares of Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a report on Friday, September 5th.

Insider Activity at Xeris Biopharma

In other news, Director Dawn Halkuff sold 42,500 shares of the stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $7.28, for a total value of $309,400.00. Following the completion of the transaction, the director owned 115,000 shares in the company, valued at approximately $837,200. This represents a 26.98% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Jeffrey W. Sherman sold 42,232 shares of the stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $7.92, for a total transaction of $334,477.44. Following the completion of the transaction, the director owned 219,188 shares of the company’s stock, valued at approximately $1,735,968.96. This represents a 16.15% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 207,732 shares of company stock valued at $1,550,437. Company insiders own 4.56% of the company’s stock.

Institutional Investors Weigh In On Xeris Biopharma

A number of hedge funds have recently made changes to their positions in the company. Corient Private Wealth LLC acquired a new stake in shares of Xeris Biopharma during the 2nd quarter worth about $320,000. Osaic Holdings Inc. grew its holdings in Xeris Biopharma by 9.7% during the 2nd quarter. Osaic Holdings Inc. now owns 42,709 shares of the company’s stock worth $199,000 after acquiring an additional 3,774 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Xeris Biopharma by 7.6% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 32,167 shares of the company’s stock worth $150,000 after acquiring an additional 2,264 shares during the last quarter. Squarepoint Ops LLC grew its holdings in Xeris Biopharma by 1,679.1% during the 2nd quarter. Squarepoint Ops LLC now owns 284,567 shares of the company’s stock worth $1,329,000 after acquiring an additional 268,572 shares during the last quarter. Finally, State of Wyoming bought a new stake in Xeris Biopharma during the 2nd quarter worth about $164,000. Institutional investors and hedge funds own 42.75% of the company’s stock.

Xeris Biopharma Stock Performance

Xeris Biopharma stock opened at $8.20 on Monday. The firm has a market cap of $1.32 billion, a PE ratio of -39.05 and a beta of 0.39. The firm’s 50 day moving average price is $7.33 and its two-hundred day moving average price is $5.65. Xeris Biopharma has a twelve month low of $2.73 and a twelve month high of $8.51.

Xeris Biopharma (NASDAQ:XERS) last posted its earnings results on Thursday, August 7th. The company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.03) by $0.02. The business had revenue of $67.71 million during the quarter, compared to the consensus estimate of $64.58 million. Equities analysts anticipate that Xeris Biopharma will post -0.41 EPS for the current fiscal year.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.